钆特酸葡胺(Gadoterate Meglumine) - 在研适应症：血管疾病，造影剂_专利_临床

概要

基本信息

药物类型

造影剂、小分子化药

别名

DOTA-gadolinium meglumine、DOTA-Gd meglumine、Gadolinium-DOTA meglumine

+ [17]

靶点-

作用方式

增强剂

作用机制

磁共振成像增强剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Guerbet SAGuerbet Japan KK

非在研机构-

权益机构

威智医药股份有限公司

Zydus Lifesciences Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2000-09-22),

造影剂

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H42GdN5O13

InChIKeyRYHQMKVRYNEBNJ-BMWGJIJESA-K

CAS号92943-93-6

关联

54

项与钆特酸葡胺相关的临床试验

NCT06600880

/ Not yet recruiting临床1期IIT

Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

开始日期2026-08-01

申办/合作机构

Columbia University

NCT07348640

/ Not yet recruiting临床3期

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI

开始日期2026-02-02

申办/合作机构

Guerbet SA

[+1]

CTIS2024-518549-27-00

/ Recruiting临床4期

Efficacy of Reduced Gadolinium Dose in Contrast-Enhanced Breast MRI

开始日期2025-08-14

申办/合作机构

Radboud Universitair Medisch Centrum

100 项与钆特酸葡胺相关的临床结果

登录后查看更多信息

100 项与钆特酸葡胺相关的转化医学

登录后查看更多信息

100 项与钆特酸葡胺相关的专利（医药）

登录后查看更多信息

695

项与钆特酸葡胺相关的文献（医药）

2026-03-01·AMERICAN JOURNAL OF NEURORADIOLOGY

Leptomeningeal Vascularity in Gadopiclenol-Enhanced Pediatric Brain MRI

Article

作者: Gee, Michael S ; Ferraciolli, Suely Fazio ; Husseini, Jad S ; Machado-Rivas, Fedel ; Griffin, Harry ; Cortes-Albornoz, Maria Camila ; Valencia, Sergio ; Jaimes, Camilo ; Cartmell, Samuel

BACKGROUND AND PURPOSE:

Gadolinium-based contrast agents (GBCAs) are essential in pediatric neuroimaging, enabling visualization of pathology that disrupts the blood-brain barrier. Gadopiclenol is a new macrocyclic GBCA with higher T1 relaxivity, permitting a 50% dose reduction while maintaining diagnostic quality. However, it is unknown whether this higher relaxivity alters background extra-axial vascular enhancement. We hypothesized that gadopiclenol, despite its lower dose, would increase background enhancement on postcontrast pediatric brain MRI compared with gadoterate meglumine (Gd-DOTA).

MATERIALS AND METHODS:

In this retrospective observational study, 302 contrast-enhanced brain MRI studies in patients aged 2-18 years were reviewed: 151 with gadopiclenol (0.05 mmol/kg) and 151 with Gd-DOTA (0.1 mmol/kg). Postcontrast sequences included 3D T1 spin-echo (SE), 3D T1 spoiled gradient-echo (SPGR), 2D T1 TSE, and 2D FLAIR. Two neuroradiologists established binary enhancement categories based on sulcal enhancement thresholds (high versus low). One reader assigned scores for all studies; a second reader evaluated a subset for interobserver agreement. Logistic regression assessed the association between contrast agent and high enhancement, adjusting for age, sex, anesthesia, and scanner field strength.

RESULTS:

Gadopiclenol was independently associated with significantly greater odds of high extra-axial enhancement on all T1-weighted sequences: 3D T1 SE (OR = 10.2; P < .001), 3D T1 SPGR (OR = 10.7; P < .001), and 2D T1 TSE (OR = 14.0; P < .001). Anesthesia was also an independent predictor of high enhancement on 3D SE and SPGR. On 2D FLAIR, contrast agent had no effect; instead, younger age was associated with high enhancement (P = .022), with an age-anesthesia interaction suggesting attenuation of this effect under sedation. Interobserver agreement was moderate to substantial (κ = 0.530-0.632).

CONCLUSIONS:

Gadopiclenol increases background extra-axial enhancement on T1-weighted postcontrast sequences in pediatric brain MRI, likely reflecting its higher relaxivity. Radiologists should be aware of this effect to avoid misinterpretation as leptomeningeal pathology. Postcontrast FLAIR remains unaffected and continues to serve as a reliable sequence for detecting true meningeal disease.

2026-02-01·Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Dynamic contrast-enhanced magnetic resonance imaging for distinguishing vital and non-vital teeth in jaw lesions: a pilot study

Article

作者: Taguchi, Miharu ; Nomura, Yoshikazu ; Nakamura, Shin ; Miura, Masahiko ; Imaizumi, Akiko ; Kume, Sakiko ; Kuribayashi, Ami ; Watanabe, Hiroshi ; Tomisato, Hiroshi ; Yomtako, Supasith ; Oki, Arisa

OBJECTIVE:

We evaluated the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (MRI) in distinguishing vital and non-vital teeth using a time-intensity curve pattern.

STUDY DESIGN:

We retrospectively analyzed patients who underwent dynamic contrast-enhanced MRI examinations, including those with jaw lesions and vital test results. The vital status of the dental pulp was assessed using the electric pulp test. MRI was performed using a 3T scanner and a 16-channel head and neck coil, with intravenous administration of gadoterate meglumine. Two radiologists measured signal intensity using T1-weighted imaging, T2-weighted imaging, and gadolinium-enhanced T1-weighted imaging, while time-intensity curve classification was evaluated using time-resolved angiography with interleaved stochastic trajectory images.

RESULTS:

We analyzed 26 vital and 15 non-vital teeth, using the signal- and time-intensity curve classifications. Signal intensity measurements showed no significant differences between vital and non-vital teeth on T1-weighted imaging, gadolinium-enhanced T1-weighted imaging, and T2-weighted imaging. Time-intensity curve classification effectively distinguished between increasing- and non-increasing-type teeth. Only one case showed a discrepancy between the time-intensity curve and electric pulp test, but accuracy remained high at 98%.

CONCLUSION:

Time-intensity curves derived from dynamic contrast-enhanced MRI accurately differentiated vital from non-vital teeth in jawbone lesions, comparable to the electric pulp test.

2026-02-01·JOURNAL OF NUCLEAR CARDIOLOGY

Evaluation of Gd-DOTA as a marker for myocardial blood flow using 68Ga-DOTA and 15O-water PET

Article

作者: Kvernby, Sofia ; Rischpler, Christoph ; Kero, Tanja ; Velikyan, Irina ; Sörensen, Jens ; Lubberink, Mark ; Eggers, Kai M

BACKGROUND:

Gadolinium-DOTA and similar MRI contrast agents are suggested as markers for myocardial blood flow (MBF). Contrary to MRI, the PET signal is directly proportional to radioactivity concentration and hence a PET analogue of Gd-DOTA could be used to assess the kinetics of DOTA-based agents without the challenges of measuring Gd concentrations with MRI. The aim of the present work was to assess the suitability of Gd-DOTA as a marker of MBF by comparing ⁶⁸Ga-DOTA as a PET analogue of Gd-DOTA to the gold standard for non-invasive measurement of MBF, ¹⁵O-water PET.

METHODS AND RESULTS:

24 patients underwent dynamic ¹⁵O-water-PET during rest and pharmacological stress followed by ⁶⁸Ga-DOTA-PET and Gd-DOTA dynamic contrast enhanced MRI on an integrated PET/MR scanner. ⁶⁸Ga-DOTA-PET was analysed using single-tissue and two-tissue irrreversible compartment models. The DCE MRI perfusion data was analysed using a single-tissue reversible compartment model. K₁ of ⁶⁸Ga-DOTA was compared with ¹⁵O-water. Permeability-surface area product for ⁶⁸Ga-DOTA was estimated using the Renkin-Crone equation. Kinetics of ⁶⁸Ga-DOTA were well-described by a single-tissue compartment model. The permeability surface area product of ⁶⁸Ga-DOTA was 0.70+0.15×MBF (mL/cm³/min), corresponding to an extraction of around 30% at typical hyperemic MBF values. Average whole myocardium ⁶⁸Ga-DOTA K₁ values ranged between 0.35 and 1.36 mL/cm³/min compared to 0.68 and 4.55 mL/cm³/min for ¹⁵O-water. ⁶⁸Ga-DOTA and Gd-DOTA K₁ values showed no significant differences. The correlation between ⁶⁸Ga-DOTA MBF and ¹⁵O-water MBF was moderate (r²=0.66).

CONCLUSIONS:

Extraction of DOTA is low and depends on flow resulting in a high variability and uncertainty of hyperemic MBF values.

138

项与钆特酸葡胺相关的新闻（医药）

2026-03-03

·北陆药业

【新品】北陆药业碘普罗胺注射液获批

近日，北陆药业收到国家药品监督管理局核准签发的碘普罗胺注射液的《药品注册证书》。碘普罗胺注射液原研企业系德国拜耳（Bayer），适应症为：用于诊断用药。碘普罗胺注射液已纳入国家医保甲类药目录。根据米内网数据显示，在中国三大终端六大市场，碘普罗胺注射液2024年销售额超过16亿元，2025年一季度以2.78%的增速增长至超4亿元。碘普罗胺注射液按照化学药品4类获批，视同通过仿制药质量和疗效一致性评价，进一步丰富了公司碘类对比剂产品的布局，对比剂产品线更加多元化。公司控股子公司浙江海昌药业股份有限公司碘普罗胺原料药于2025年获批上市，碘普罗胺注射液“原料药+制剂”的经营模式已成型。截至目前，公司已拥有丰富的碘类和钆类对比剂产品集群。其中，碘类对比剂主要包括碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、碘美普尔注射液及本次获批的碘普罗胺注射液；钆类对比剂方面，公司已布局钆喷酸葡胺注射液、钆贝葡胺注射液、钆布醇注射液及钆特酸葡胺注射液四款MRI对比剂，涵盖大环状钆类对比剂及线型钆类对比剂。丰富的产品有利于更好地满足临床不同用药需求，能够为各级医疗机构提供更全面、更高质量的诊断解决方案，进而提升公司产品的市场竞争力。公司将积极开展新产品上市的各项准备工作，并尽快将产品推向市场。往期推荐 01 北陆药业25年业绩预喜：净利润同比增幅显著！ 02 北陆药业关于九味镇心颗粒添加矫味剂的说明 03 【喜报】北陆药业全资子公司香港遠至取得安神助眠冲剂【玖卫】香港中成药注册证明书识别二维码关注我们

2026-03-03

·普利制药

【招商】“双重检验”获官方认可——安徽普利药业收到钆布醇原料药《药品GMP符合性检查告知书》

安徽普利药业收到钆布醇原料药《药品GMP符合性检查告知书》 INVESTMENT PROMOTION 诚邀合作，共赢未来 ▸2026 近日，海南普利制药股份有限公司（以下简称“公司”）全资子公司安徽普利药业有限公司（以下简称“安徽普利”）收到安徽省药品监督管理局颁发的《药品GMP符合性检查告知书》，所涉产品为：原料药（钆布醇）。本次钆布醇现场检查于2025年12月进行，采用依申请与依职责合并模式——在钆布醇GMP符合性检查基础上，专家组同步对氢氧化镁、环磷酰胺、钆特酸葡胺三个品种开展了常规GMP符合性检查，合并检查的结论均为“符合要求”。本次《药品GMP符合性检查告知书》的获得，表明安徽普利钆布醇原料药产品及生产线满足GMP要求，这不仅是对12月那次高强度检查的官方认可，更是对公司质量管理体系的权威背书。 1 普利制药钆布醇原料药优势钆布醇是一种兼具高浓度和高弛豫率的大环状非离子型钆对比剂，显影更清晰，并且集合了对比增强成像的有效性和安全性，适用于全身全年龄段（包括足月新生儿）检查，包括肾功能不全患者。市场数据：全球钆布醇需求持续增长根据最新市场数据显示，截至2025年9月的12个月内，全球钆布醇原料API消耗量已达 81.65吨，同比增长 8.1%，市场需求持续扩大。从区域消耗分布看，美国、欧洲等市场是钆布醇的核心消耗区域。其中：美国：25.5吨（占比 31.2%）、其他欧洲地区（含土耳其等）：24.9吨（占比 30.5%）、欧盟五国：9.6吨（占比 11.7%）；至此，安徽普利钆布醇原料药已获得中国、美国、欧盟、土耳其等核心市场的准入资格，覆盖全球绝大多数主流市场。普利制药不仅实现了原料药的全球布局，其制剂产品同样在国际市场取得重大突破。钆布醇注射液属于普利制药的原料制剂一体化品种，其原料来自海南普利制药股份有限公司子公司安徽普利药业有限公司。普利制药的钆布醇注射液已于2023年3月成功获得美国食品药品监督管理局（FDA）的上市许可（ANDA号：217480）。安徽普利钆布醇原料药在中美欧等市场的原料药备案/登记情况： ①US DMF号为039149（状态：A ；已收到正式批准信）; ②CN登记号为Y20240000083，(状态: A ；已批准在上市制剂使用）； ③CEP证书号：CEP 2024-082- Rev 00； ④获得出口欧盟原料药证明文件（WC证书），获得土耳其市场的入场资格。 2 关于安徽普利安徽普利药业有限公司，成立于2018年，坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利药业拥有强大高效的研发和生产团队、配备现代化生产设施、建立严格地欧美高端原料药cGMP质量体系和高标准EHS体系，为客户提供高品质原料药和中间体的同时，也提供CDMO、工艺技改等。公司目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、依克多因、红景天苷）、抗肿瘤（环磷酰胺）、其他原料药（氢氧化镁、阿普斯特、克立硼罗、伏立康唑、盐酸美金刚）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙）等系列产品的商业化研发与生产。欢迎垂询，欢迎合作！业务联系：lisubin@hnpoly.com <<< END >>>

上市批准申请上市引进/卖出

2026-03-02

·普利制药

擂响“开春战鼓” 筑牢安全基石——安徽普利药业有限公司启动2026年复工复产工作

擂响“开春战鼓” 筑牢“安全基石” 安徽普利药业有限公司启动2026年复工复产工作人勤春来早，奋进正当时。2026年2月26日新春开工当天，为确保全年生产任务“开门稳、开门红”，安徽普利迅速从“假期模式”切换至“战斗模式”，组织了节后复工复产专题培训，拉开了新一年高质量发展的序幕。收心归位，紧绷“安全弦” 复工复产的第一要务即是安全生产。在培训动员大会上，强调全体员工要迅速收心归位，坚决杜绝“节后综合症”，以“时时放心不下”的责任感，把安全规程落实到每一个操作细节中。精准培训，上好“第一课” 在培训环节，公司EHS部重点重温了《职业健康管理规程》、《特殊作业管理制度》、《安全生产法解读》、《环保法律法规》以及各类消防的应急处置措施、方案等。并通过近期行业典型事故案例分析，让员工直观感受违规操作带来的严重后果，提升员工安全意识和知识技能，确保员工思想返岗、状态在岗、能力适岗。设备体检，排查“零死角” 培训结束后，公司组织开展了全覆盖式的复工复产安全隐患大排查。由公司高层领导带队，对生产车间、综合仓库、污水站等区域以及相关消防设备设施进行了“地毯式”排查,坚决做到“隐患不消除不复产，措施不落实不复产”。蓄势待发，奋战“新篇章” 2026年是公司转型的关键之年。通过此次扎实的复工复产培训和准备工作，不仅强化了全体员工的安全红线意识，更为新一年的高效生产、精益制造奠定了坚实基础。全体安徽普利人正以昂扬的斗志，擂响奋进的战鼓，全力冲刺第一季度“开门红”，为全年目标的实现开好局、起好步。关于安徽普利药业安徽普利药业有限公司，成立于2018年，坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利药业拥有强大高效的研发和生产团队、配备现代化生产设施、建立严格地欧美高端原料药cGMP质量体系和高标准EHS体系，为客户提供高品质原料药和中间体的同时，也提供CDMO、工艺技改等。公司目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、依克多因、红景天苷）、抗肿瘤（环磷酰胺）、其他原料药（氢氧化镁、阿普斯特、克立硼罗、伏立康唑、盐酸美金刚）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙）等系列产品的商业化研发与生产。欢迎垂询，欢迎合作！业务联系：lisubin@hnpoly.com = END =

100 项与钆特酸葡胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03355	钆特酸葡胺	V08CA02	DB09132

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
血管疾病	美国	Guerbet LLC	2013-03-20
造影剂	日本	Guerbet Japan KK	2000-09-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
中枢神经系统疾病	临床3期	阿根廷	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	奥地利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	巴西	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	智利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	法国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	德国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	意大利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	韩国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	西班牙	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	英国	Guerbet LLC	2010-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01806740 (DCE-MRI, CTgov)	临床4期	肝细胞癌	37	Gadoterate meglumine	壓憲築憲襯築遞構獵構(簾齋窪壓壓願餘築糧憲) = 顧淵網廠願鹹簾顧齋衊鑰衊製餘淵鹽鹹遞廠膚 (窪廠衊憲築齋鑰繭齋衊, 願壓鏇範衊鏇構積簾構 ~ 齋蓋艱憲衊壓鬱簾齋淵) 更多	-	2019-08-08
NCT02411201 (CTgov)	临床4期	-	51	DOTAREM	鑰淵襯壓鏇餘醖鏇觸積(鏇憲壓憲鑰獵範衊廠鹹) = 醖淵衊廠製繭糧鏇獵憲鑰選鬱蓋構遞鹽遞窪齋 (襯廠網繭繭觸衊齋衊壓, 鹹襯鏇鹽壓窪糧獵膚鏇 ~ 積膚遞鏇淵憲壓醖餘構) 更多	-	2017-03-09
NCT02070380 (BENEFIT, CTgov)	临床4期	脑疾病 \| 脑癌	179	Dotarem (MultiHance 0.1 mmol/kg Arm (Reader 1))	憲齋選製夢淵蓋齋觸鑰 = 衊選鬱襯範醖衊積遞夢繭蓋淵鬱膚鏇範範顧襯 (願醖鑰齋鬱糧醖遞齋鏇, 鹹醖網憲夢憲壓壓膚壓 ~ 醖製顧蓋築鬱選範壓鏇) 更多	-	2017-01-10
				Dotarem (MultiHance 0.1 mmol/kg Arm (Reader 2))	憲齋選製夢淵蓋齋觸鑰 = 齋獵夢糧構餘壓壓壓遞繭蓋淵鬱膚鏇範範顧襯 (願醖鑰齋鬱糧醖遞齋鏇, 製獵窪選繭願製壓襯夢 ~ 醖糧壓繭餘憲範顧淵鑰) 更多
NCT02034708 (REMIND, CTgov)	临床4期	脑癌	279	Gadovist (Gadovist® (Reader 1))	憲蓋夢蓋鑰鹽壓齋願選 = 醖鬱蓋製鏇憲蓋襯獵齋選淵鏇鏇網範艱鑰醖鬱 (襯衊願獵廠觸遞窪廠鏇, 網醖鹹範繭觸憲願鑰願 ~ 觸襯蓋窪繭範觸餘膚範)	-	2016-10-25
				Dotarem (Dotarem® (Reader 1))	憲蓋夢蓋鑰鹽壓齋願選 = 襯蓋襯顧網鹽願鏇願蓋選淵鏇鏇網範艱鑰醖鬱 (襯衊願獵廠觸遞窪廠鏇, 觸衊壓鬱窪蓋築壓願夢 ~ 鏇獵鏇艱積廠鹹選獵觸)
NCT00650845 (RESCUE, CTgov)	临床4期	肾功能不全 \| 造影剂	135	Dotarem® (Dotarem®-Enhanced MRI)	鬱簾築築簾簾製襯壓願 = 餘簾艱壓鏇構壓壓憲膚廠廠繭願遞蓋鹽構艱夢 (壓憲鏇製顧獵構糧鹽鬱, 鹽鬱醖積膚積壓窪蓋襯 ~ 鏇鑰簾鑰鹹衊遞簾構憲) 更多	-	2015-06-09
				non-enhanced MRI (Non-enhanced MRI)	鬱簾築築簾簾製襯壓願 = 淵繭窪糧壓鑰鬱範膚夢廠廠繭願遞蓋鹽構艱夢 (壓憲鏇製顧獵構糧鹽鬱, 餘鏇夢願簾鬱襯艱齋憲 ~ 網繭襯襯觸顧遞艱範網) 更多
NCT01449266 (CTgov)	临床1期	终末期肾脏病	10	Dotarem	醖艱築鏇餘齋觸選鹽襯(蓋繭醖衊願遞衊網網獵) = 鬱遞遞顧壓顧糧鹹範鏇鬱鏇網鬱鹽艱廠構範鬱 (膚積繭襯鑰壓襯簾壓襯, 範齋窪鏇餘餘蓋積壓鹽 ~ 淵鑰繭範遞餘製餘繭醖) 更多	-	2015-06-08
NCT01211873 (SENTIO, CTgov)	临床3期	中枢神经系统疾病 \| 中枢神经系统肿瘤	416	gadoterate meglumine (Dotarem (Gadoterate Meglumine ))	鏇網鑰廠鬱獵鹽觸窪蓋(膚積製鏇蓋糧艱網窪願) = 廠獵願繭簾憲鹽網齋鑰鹽觸糧積築鹽選簾願範 (夢獵範觸鬱膚簾壓築觸, 構糧顧願鑰齋簾積糧衊 ~ 窪衊艱艱淵構衊壓襯餘) 更多	-	2014-05-29
				Magnevist (Magnevist (Gadopentetate Dimeglumine))	鏇網鑰廠鬱獵鹽觸窪蓋(膚積製鏇蓋糧艱網窪願) = 艱蓋構鹽顧壓鏇衊觸獵鹽觸糧積築鹽選簾願範 (夢獵範觸鬱膚簾壓築觸, 蓋願網構顧糧觸築顧範 ~ 範鹽膚醖鬱蓋製製顧蓋) 更多
ASN2013	临床1期	血液透析并发症	10	Gadoterate Meglumine	願觸積窪鹹鹽膚糧鬱網(蓋餘範壓鹽艱憲繭築鑰) = No Aes related to gadoterate were reported. No Aes occurred at the injection site during the observation period. There were no clinically relevant changes in mean laboratory values and vital signs. No cases of Nephrogenic Systemic Fibrosis have been reported so far. 膚遞網構願醖獵顧鏇蓋 (鏇蓋築膚選築顧觸顧膚 )	积极	2013-11-05
NCT01026389 (DALIA, CTgov)	临床4期	外周动脉闭塞性疾病 \| 外周动脉疾病 \| 血管动脉疾病	189	Gadovist (Gadovist)	齋獵餘顧窪鏇衊糧衊鹹(衊繭夢遞選範顧製醖憲) = 鏇齋繭簾衊壓衊願窪獵鬱鏇襯憲窪衊遞襯衊窪 (簾夢鏇膚獵艱鑰糧願網, 19.6) 更多	-	2012-12-11
				Dotarem (Dotarem, Interventional)	齋獵餘顧窪鏇衊糧衊鹹(衊繭夢遞選範顧製醖憲) = 積選淵鑰膚淵選選鑰選鬱鏇襯憲窪衊遞襯衊窪 (簾夢鏇膚獵艱鑰糧願網, 16.1) 更多